The stock of Immunovant Inc (IMVT) has seen a 3.34% increase in the past week, with a 14.70% gain in the past month, and a -8.38% decrease in the past quarter. The volatility ratio for the week is 4.69%, and the volatility levels for the past 30 days are at 5.22% for IMVT. The simple moving average for the past 20 days is 3.88% for IMVT’s stock, with a -26.19% simple moving average for the past 200 days.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
IMVT has 36-month beta value of 0.62. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for IMVT is 68.57M, and currently, short sellers hold a 29.05% ratio of that float. The average trading volume of IMVT on June 27, 2025 was 1.57M shares.
IMVT) stock’s latest price update
Immunovant Inc (NASDAQ: IMVT) has seen a rise in its stock price by 4.06 in relation to its previous close of 15.75. However, the company has experienced a 3.34% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-02 that Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Jefferies repeating the rating for IMVT by listing it as a “Hold.” The predicted price for IMVT in the upcoming period, according to Jefferies is $20 based on the research report published on March 03, 2025 of the current year 2025.
Raymond James gave a rating of “Outperform” to IMVT, setting the target price at $36 in the report published on October 10th of the previous year.
IMVT Trading at 8.40% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.45% of loss for the given period.
Stock Fundamentals for IMVT
The net margin for Immunovant Inc stands at -2586.5. Equity return is now at value -62.46, with -57.32 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -3835.45.
When we switch over and look at the enterprise to sales, we see a ratio of 13047.22. The receivables turnover for the company is 0.08for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.16.
Conclusion
To put it simply, Immunovant Inc (IMVT) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
